Form 144 PRECISION BIOSCIENCES INC For: 19 February

Precision Biosciences Inc. filed a Form 144 with the U.S. Securities and Exchange Commission on February 19, 2024, announcing its intent to transfer a substantial amount of its common stock. The filing is a routine disclosure required under the Securities Act, allowing the company and its shareholders to comply with regulatory reporting obligations and to inform the market about pending share sales. The Form 144 indicates that one or more insiders will sell a portion of the company’s common stock within the next 60 days. While the filing does not disclose the exact number of shares, the transaction would be reported in the company’s regular earnings or shareholder communications. The disclosure underscores Precision Biosciences’ commitment to transparency and regulatory compliance as it continues to drive its biotherapeutic research and development initiatives. This filing serves as a formal notice to investors that planned share sales are underway and provides the SEC with the necessary record of the transaction as it adheres to Section 4(a)(2) of the Securities Act.